A generic research paradigm for identification and validation of early molecular diagnostics and new therapeutics in common disorders

Keith D. Coon, Travis Dunckley, Dietrich A. Stephan

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Genetically complex disorders continue to confound investigators because of their many underlying factors, both genetic and environmental. In order to tease apart the heritable from the non-heritable contributions to disease, clinicians are relying on researchers in the rapidly expanding fields of high-throughput genomics to identify surrogate clinical endpoints, called biomarkers, that provide a measure of the probability that an individual will succumb to the disease in question. The goals of current biomedical research into complex disorders are to identify and utilize these biomarkers, not only for early detection, but also for personalized treatment with knowledge-guided therapeutics. As the identification of these biomarkers is basically a problem of discovery, we discuss new insights into biomarker detection utilizing the most current genomic technologies available. Additionally, we present here a generic paradigm for the validation of such molecular diagnostics as well as new treatment modalities for complex and increasingly common diseases. Lastly, we delve into the ways genomic biomarkers might be implemented in a clinical setting to allow the subsequent application of targeted therapeutics, which can help the ever expanding groups of individuals experiencing these insidious diseases.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalMolecular Diagnosis and Therapy
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Molecular Pathology
Biomarkers
Research
Therapeutics
Research Personnel
Genomics
Biomedical Research
Technology

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

A generic research paradigm for identification and validation of early molecular diagnostics and new therapeutics in common disorders. / Coon, Keith D.; Dunckley, Travis; Stephan, Dietrich A.

In: Molecular Diagnosis and Therapy, Vol. 11, No. 1, 01.01.2007, p. 1-14.

Research output: Contribution to journalReview article

@article{f878b3d4deac4bfd8decbac5d9e9b567,
title = "A generic research paradigm for identification and validation of early molecular diagnostics and new therapeutics in common disorders",
abstract = "Genetically complex disorders continue to confound investigators because of their many underlying factors, both genetic and environmental. In order to tease apart the heritable from the non-heritable contributions to disease, clinicians are relying on researchers in the rapidly expanding fields of high-throughput genomics to identify surrogate clinical endpoints, called biomarkers, that provide a measure of the probability that an individual will succumb to the disease in question. The goals of current biomedical research into complex disorders are to identify and utilize these biomarkers, not only for early detection, but also for personalized treatment with knowledge-guided therapeutics. As the identification of these biomarkers is basically a problem of discovery, we discuss new insights into biomarker detection utilizing the most current genomic technologies available. Additionally, we present here a generic paradigm for the validation of such molecular diagnostics as well as new treatment modalities for complex and increasingly common diseases. Lastly, we delve into the ways genomic biomarkers might be implemented in a clinical setting to allow the subsequent application of targeted therapeutics, which can help the ever expanding groups of individuals experiencing these insidious diseases.",
author = "Coon, {Keith D.} and Travis Dunckley and Stephan, {Dietrich A.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1007/BF03256218",
language = "English (US)",
volume = "11",
pages = "1--14",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - A generic research paradigm for identification and validation of early molecular diagnostics and new therapeutics in common disorders

AU - Coon, Keith D.

AU - Dunckley, Travis

AU - Stephan, Dietrich A.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Genetically complex disorders continue to confound investigators because of their many underlying factors, both genetic and environmental. In order to tease apart the heritable from the non-heritable contributions to disease, clinicians are relying on researchers in the rapidly expanding fields of high-throughput genomics to identify surrogate clinical endpoints, called biomarkers, that provide a measure of the probability that an individual will succumb to the disease in question. The goals of current biomedical research into complex disorders are to identify and utilize these biomarkers, not only for early detection, but also for personalized treatment with knowledge-guided therapeutics. As the identification of these biomarkers is basically a problem of discovery, we discuss new insights into biomarker detection utilizing the most current genomic technologies available. Additionally, we present here a generic paradigm for the validation of such molecular diagnostics as well as new treatment modalities for complex and increasingly common diseases. Lastly, we delve into the ways genomic biomarkers might be implemented in a clinical setting to allow the subsequent application of targeted therapeutics, which can help the ever expanding groups of individuals experiencing these insidious diseases.

AB - Genetically complex disorders continue to confound investigators because of their many underlying factors, both genetic and environmental. In order to tease apart the heritable from the non-heritable contributions to disease, clinicians are relying on researchers in the rapidly expanding fields of high-throughput genomics to identify surrogate clinical endpoints, called biomarkers, that provide a measure of the probability that an individual will succumb to the disease in question. The goals of current biomedical research into complex disorders are to identify and utilize these biomarkers, not only for early detection, but also for personalized treatment with knowledge-guided therapeutics. As the identification of these biomarkers is basically a problem of discovery, we discuss new insights into biomarker detection utilizing the most current genomic technologies available. Additionally, we present here a generic paradigm for the validation of such molecular diagnostics as well as new treatment modalities for complex and increasingly common diseases. Lastly, we delve into the ways genomic biomarkers might be implemented in a clinical setting to allow the subsequent application of targeted therapeutics, which can help the ever expanding groups of individuals experiencing these insidious diseases.

UR - http://www.scopus.com/inward/record.url?scp=33846941520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846941520&partnerID=8YFLogxK

U2 - 10.1007/BF03256218

DO - 10.1007/BF03256218

M3 - Review article

C2 - 17286446

AN - SCOPUS:33846941520

VL - 11

SP - 1

EP - 14

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 1

ER -